China’s top health authority has granted Adcentrx Therapeutics approval to proceed with trials for ADRX-0405, an investigational STEAP1 antibody-drug conjugate aiming to treat late-stage solid tumors, including prostate cancer. Building on progress from its U.S. Phase 1a/1b study, the company aims to broaden the trial’s reach and accelerate patient enrollment by including clinical centers in China.